Evidence map›Paper›PMID 39949934›Full record

ArticleAmerican journal of cancer research2025

Overexpression of SHANK2 contributes malignant outcomes as a Hippo pathway regulator in gastric cancer.

Hiroshi Arakawa, Shuhei Komatsu, Jun Kiuchi, Taisuke Imamura, Keiji Nishibeppu, Hajime Kamiya, Yusuke Takashima, Ryo Ishida, Satoshi Hamada, Masateru Yamauchi and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Hiroshi ArakawaDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Shuhei KomatsuDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Jun KiuchiDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Taisuke ImamuraDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Keiji NishibeppuDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Hajime KamiyaDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Yusuke TakashimaDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Ryo IshidaDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Satoshi HamadaDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Masateru YamauchiDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Takuma OhashiDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Hiroki ShimizuDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Tomohiro AritaDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Hirotaka KonishiDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Atsushi ShiozakiDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Takeshi KubotaDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Hitoshi FujiwaraDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.
Hitoshi TsudaDepartment of Pathology, National Defense Medical College Hospital Saitama, Japan.
Eigo OtsujiDivision of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent studies identified that SH3 and multiple ankyrin repeat domains 2 (SHANK2) is located in a gene-amplified region 11q13 of various human cancers, and has oncogenic functions as a Hippo pathway suppressor in hepatocellular carcinoma. In this study, we tested whether SHANK2 acts as a cancer-promoting gene through its activation or overexpression in gastric cancer (GC). MATERIALS AND

methodsWe analyzed 5 GC cell lines and 172 primary tumor samples of GC, which were curatively resected in our hospital.

resultsOverexpression of SHANK2 protein was frequently detected in GC cell lines (4/5 cell lines, 80%). Knockdown of SHANK2 inhibited cell proliferation, migration and invasion of GC cells in a

conclusionsThese findings suggest that SHANK2 plays a crucial role in tumor malignant potential through the Hippo pathway suppression and highlight its usefulness as a prognostic factor and potential therapeutic target in GC.

Indexed as

gastric cancerHippo pathwayoverexpressionprognosisSHANK2

Identifiers

PMID39949934
PMCPMC11815361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.